8-K: ProKidney Secures FDA Alignment for Accelerated Approval of Rilparencel in Chronic Kidney Disease

ProKidney Corp. announced FDA alignment on the accelerated approval pathway for its lead cellular therapy, rilparencel, for patients with advanced chronic kidney disease and type 2 diabetes, with topline data for accelerated approval anticipated in Q2 2027.

Summary

• ProKidney Corp. has confirmed alignment with the U.S. Food and Drug Administration (FDA) on the accelerated approval pathway for rilparencel, its autologous cellular therapy for advanced chronic kidney disease (CKD) and type 2 diabetes.
• The FDA confirmed that the slope of estimated glomerular filtration rate (eGFR) from the ongoing Phase 3 PROACT 1 study can serve as the surrogate endpoint and primary basis for a Biologics License Application (BLA) submission under the accelerated approval pathway.
• An effect size of at least 1.5 mL/min/1.73m2/year improvement in eGFR slope (versus sham controls) is deemed an acceptable demonstration of efficacy.
• Topline data readout for eGFR slope to support an accelerated approval application is anticipated in Q2 2027.
• Nearly half of the patients required for the accelerated approval analysis have been enrolled in the PROACT 1 study.
• The FDA also confirmed that the Phase 3 PROACT 1 study can serve as the confirmatory study for full approval based on its primary time-to-event composite endpoint.
• Updated guidance on the expected timing of the confirmatory readout for full approval will be provided in 1H 2026.
• Positive topline results for the Phase 2 REGEN-007 trial were announced on July 8, 2025, showing a statistically significant 78% improvement in annual eGFR slope for Group 1 (Phase 3 dosing regimen) from -5.8 to -1.3 mL/min/1.73m2 per year, a difference of 4.6 mL/min/1.73m2 per year (p<0.001).
• The safety profile of rilparencel was consistent with previously reported study results and comparable to a kidney biopsy, with no rilparencel-related serious adverse events observed.

Sentiment

Score: 8

Explanation: The announcement of FDA alignment on an accelerated approval pathway for rilparencel, coupled with positive Phase 2 data and a clear path for the pivotal Phase 3 study to support both accelerated and full approval, represents a significant de-risking event and a major positive catalyst for the company. The financial runway into mid-2027 also provides stability.

Positives

• FDA alignment on the accelerated approval pathway for rilparencel significantly de-risks the regulatory path.
• eGFR slope has been accepted as a surrogate endpoint for accelerated approval, potentially expediting market access.
• The ongoing Phase 3 PROACT 1 study can serve for both accelerated and full approval, streamlining the development process.
• Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, indicating its potential to address unmet medical needs.
• Positive topline results from the Phase 2 REGEN-007 trial, particularly the statistically significant 78% improvement in eGFR slope in Group 1, support the efficacy of the Phase 3 dosing regimen.
• Nearly half of the patients required for accelerated approval analysis in PROACT 1 have already been enrolled, indicating good progress in the pivotal trial.
• The safety profile of rilparencel is consistent with prior studies and comparable to a kidney biopsy, with no serious adverse events reported.
• Current cash of $328 million is expected to fund operations into mid-2027, providing financial stability for ongoing development.

Negatives

• The annual decline in eGFR slope for Group 2 (exploratory dosing regimen) in the REGEN-007 trial, while showing a 50% improvement, was not statistically significant (p=0.085), suggesting this dosing regimen may be less effective or require further optimization.

Risks

• Disruptions to business or financial condition due to recent domestication to the United States.
• Inability to maintain the listing of Class A common stock on Nasdaq.
• Potential negative impact on stock price if Class A common stock is excluded from various indices.
• Inability to implement business plans, forecasts, or realize additional opportunities, potentially affected by competition or ability to grow profitably and retain key employees.
• Risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry.
• Clinical trial results may not support approval, or the FDA could require additional studies before approving drug candidates.
• Inability to raise future financing.
• Inability to obtain and maintain regulatory clearance or approval for products, and any related restrictions and limitations.
• Inability to identify, in-license, or acquire additional technology.
• Inability to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases.
• Uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities.
• Interim results from clinical programs may not be indicative of future results.
• Impact of geo-political conflict on the company's business.

Future Outlook

ProKidney anticipates topline data readout for accelerated approval of rilparencel in Q2 2027, with the Phase 3 PROACT 1 study serving as the basis for both accelerated and full approval. Updated guidance on the timing of the confirmatory readout for full approval is expected in 1H 2026. The company expects its current cash to support operating plans into mid-2027.

Management Comments

• "We are very encouraged by the FDAs support of the accelerated approval pathway for rilparencel using eGFR slope, marking a critical regulatory milestone for ProKidney."
• "This alignment allows us to move forward with clarity and conviction as we advance enrollment in our pivotal Phase 3 PROACT 1 study on the heels of the positive Phase 2 REGEN-007 topline results announced last week."
• "We look forward to our ongoing dialogue with the FDA, under RMAT designation, to bring rilparencel to patients with advanced CKD and diabetes, a patient population with high unmet clinical and societal needs."

Industry Context

Chronic Kidney Disease (CKD) affects an estimated 37 million adults in the U.S., with 1 to 2 million people in the U.S. having Stage 3b/4 CKD and diabetes, ProKidney's target population. Despite existing treatments like ACE inhibitors, ARBs, and SGLT2 inhibitors, there remains a substantial unmet need for therapies that can stabilize kidney function and delay or prevent the need for dialysis in patients with advanced CKD. Current standard of care does not prevent events in 50-75% of people with diabetic kidney disease, and while new therapies like SGLT2 inhibitors slow progression, patients still lose kidney function. Rilparencel, as a first-in-class autologous cellular therapy with RMAT designation, aims to disrupt this landscape by preserving kidney function, offering a novel approach beyond current symptomatic management or preparation for dialysis/transplantation.

Comparison to Industry Standards

• Current Standard of Care (SoC): Includes ACE inhibitors, angiotensin receptor blockers (ARBs), and SGLT2 inhibitors. These therapies aim to slow disease progression but do not prevent events in 50-75% of people with diabetic kidney disease.
• SGLT2 Inhibitors (e.g., Dapagliflozin, Canagliflozin, Empagliflozin): While dapagliflozin demonstrated a <1.0 mL/min/year difference in eGFR, it achieved a reduction in clinically important events. However, patients on SGLT2 inhibitors still continue to lose kidney function and progress to Stage 4/5 CKD. For example, the DAPA-CKD trial showed dapagliflozin resulted in an approximate eGFR change of -2.86 mL/min/1.73m2 per year versus SoC at -3.79 mL/min/1.73m2 per year.
• Finerenone (Selective MRA): The FIDELIO-DKD trial showed a 7% reduction in kidney outcomes in patients with type 2 diabetes and CKD.
• Semaglutide (GLP-1RA): The FLOW trial showed an 11% reduction in chronic kidney disease events in patients with type 2 diabetes.
• Rilparencel (REGEN-007 Group 1): Demonstrated a 4.6 mL/min/1.73m2 per year improvement in eGFR slope (from -5.8 to -1.3 mL/min/1.73m2 per year), which is a significant stabilization/improvement compared to the continued decline seen with existing therapies. This suggests rilparencel has the potential to offer a more direct and substantial impact on kidney function preservation than current options, which primarily focus on slowing decline rather than stabilizing or improving eGFR slope to this extent.

Stakeholder Impact

• Shareholders: Positive impact due to significant regulatory de-risking, potential for earlier market entry via accelerated approval, and positive clinical trial results, which could lead to increased share price.
• Patients with Advanced CKD and Type 2 Diabetes: Potential for a novel, effective treatment (rilparencel) to preserve kidney function and delay or prevent the need for dialysis, addressing a high unmet clinical need.
• Healthcare Providers: Potential new therapeutic option to manage advanced CKD in diabetic patients, offering a different mechanism of action compared to existing treatments.
• Regulatory Authorities (FDA): Continued collaboration under RMAT designation to facilitate the development and potential approval of a therapy for a serious condition.

Next Steps

• Continue enrollment of patients in the registrational Phase 3 PROACT 1 study.
• Submit full REGEN-007 results as a late-breaking clinical trial to the American Society of Nephrology (ASN) Kidney Week.
• Provide an update on rilparencel mechanism of action in 2H 2025.
• Provide updated guidance on the expected timing of the confirmatory readout for full approval in 1H 2026.
• Anticipate topline data readout for accelerated approval in Q2 2027.

Key Dates

Recommendation

Keywords

ProKidney, rilparencel, CKD, chronic kidney disease, FDA, accelerated approval, eGFR slope, Phase 3, PROACT 1, REGEN-006, REGEN-007, cellular therapy, RMAT, type 2 diabetes, kidney failure, biotechnology, clinical trial, biologics, renal